CClinicalTrials.gg
CompletedNCT02795039Updated Mar 9, 2017

Bioequivalence Study of Fulvestrant Injection 50 mg/mL in Healthy Post-menopausal Female Subjects

A Phase 1 interventional study of Fulvestrant and Fulvestrant in Healthy, sponsored by Fresenius Kabi. Completed at 3 sites in Canada. Open to female participants aged 40 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-09.

Sponsored by Fresenius Kabi · Phase 1, Interventional, and Other

Phase
Phase 1
Study type
Interventional
Enrollment
266
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
Female
01

Study summary

The purpose of this study is to demonstrate bioequivalence between the test drug product, fulvestrant Injection, 50 mg/mL, and the Reference Listed Drug, Faslodex® Injection, 50 mg/mL.

Read the detailed description

This study is being conducted to establish bioequivalence between sponsor's test product [fulvestrant Injection, 50 mg/mL (Manufactured for Fresenius Kabi, USA)] and reference listed drug [Faslodex® Injection, 50 mg/mL, (Distributed by AstraZeneca Pharmaceuticals, USA] after intramuscular administration of a 250 mg dose (5 mL injection) into the upper outer quadrant of the right buttock to normal, healthy, nonsmoking post-menopausal female subjects.

The order of receiving the test product (T) or reference listed drug (R) for each subject during the study will be determined according to a randomization schedule.

Subjects will be allocated with a ratio of 1:1 to both treatment groups (i.e. T and R).

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Fresenius Kabi is the lead sponsor of 51 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Normal, healthy, non smoking post-menopausal female subjects between the ages of 40 and 65 years (inclusive) Note: Postmenopausal is defined as 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels >40 mIU/mL. The amenorrhea should not be due to lactation
  • Body Mass Index (BMI = weight/height2) greater than or equal to 18.5 kg/m2 and less than or equal to 29.9 kg/m2
  • Physical examination, 12-lead electrocardiogram (ECG) and vital signs without any clinically significant findings
  • Negative for urine drugs of abuse screen, urine nicotine (cotinine) screen, and breath alcohol screen.
  • Negative for hepatitis B-surface antigen, hepatitis C and Human Immunodeficiency Virus (HIV)
  • Clinical laboratory values within the acceptable range, unless deemed clinically not significant by the principal investigator or sub-investigator.
  • Availability of the subject for the entire study period and willingness of the subject to adhere to protocol requirements as evidenced by signing the Informed Consent Form (ICF).

Exclusion criteria

Exclusion Criteria:

  • History of clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, musculoskeletal, psychiatric, or cardiovascular disease or malignancies or any other condition which, in the opinion of the principal investigator or sub-investigator, would jeopardize the safety of the subject or impact the validity of the study results.
  • A history of allergic or adverse response(s) to fulvestrant, castor oil, benzyl alcohol, benzyl benzoate, polysorbate 80, α-tocopherol or any other comparable or similar products.
  • Smoking or use of tobacco products within 6 months prior to the first dose of study drug or during the study
  • Positive urine pregnancy test at screening or serum pregnancy test prior to administration of study drug.
  • History of any bleeding disorders
  • Consumption of alcohol exceeding 10 drinks/ week in the previous 1 year
  • Intolerance to/fear of venipuncture, needles or blood draws
  • Have consumed any products or undergone any procedures mentioned under "restriction table" in protocol
  • Surgically-induced post menopausal females
05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
266 participants (actual)

Study arms

  • Experimental
    Fulvestrant 50mg/mL (Fresenius Kabi)

    5 mL intramuscular injection

    Drug: Fulvestrant

  • Active comparator
    Fulvestrant 50 mg/mL (Faslodex®)

    5 mL intramuscular injection

    Drug: Fulvestrant

Interventions

  • DrugFulvestrant

    Single 5 mL intramuscular injection (slowly over 1-2 minutes) of Fulvestrant into the right buttock (upper outer quadrant)

  • DrugFulvestrant

    Single 5 mL intramuscular injection (slowly over 1-2 minutes) of Faslodex® (Fulvestrant) into the right buttock (upper outer quadrant)

    Also known as: Faslodex

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration

    Time frame: 0-238 days

  2. Area under the plasma concentration versus time curve (AUC0-238d) of fulvestrant

    Time frame: 0-238 days

Secondary outcomes

  1. Area under the plasma concentration versus time curve (AUC0-28d) of fulvestrant

    Time frame: 0-28 day

  2. Area under the plasma concentration versus time curve from time zero to the last measurable concentration (AUC0-t)

    Time frame: 0-238 days

  3. Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC0-∞)

    Time frame: 0-238 days

  4. Time to Reach the Maximum Plasma Concentration (Tmax)

    Time frame: 0-238 days

  5. Elimination Half-life Period (t1/2)

    Time frame: 0-238 days

  6. Terminal Slope (λz)

    Time frame: 0-238 days

  7. Residual area in percentage (AUC_%Extrap_obs)

    Time frame: 0-238 days

  8. Injection site pain assessment

    Time frame: 0-8 days

07

Study locations

3 sites
  • Lambda Therapeutic Research Inc.
    Toronto, Ontario M1L4S4, Canada
  • BioPharma Services Inc.
    Toronto, Ontario M9L 3A2, Canada
  • Algorithme Pharma Inc.
    Mount Royal, Quebec H3P 3P1, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02795039
Lead sponsor
Fresenius Kabi
Responsible party
Sponsor
First posted
Jun 9, 2016
Start date
Jun 2016
Primary completion
Mar 3, 2017
Completion
Mar 3, 2017
Last update
Mar 9, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion